Clinical Trials Browser

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Disease, Recurrence, Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Down Syndrome, Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Neoplasms, Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Recurrence, Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute, Neoplasm, Residual

Clinical Trials

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

MO-TRANS

cAMeLot-2

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

IMPACT-AML

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

QuANTUM-WILD

REVEAL-ND NPM1

TROPHY-15

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

AML-DS-2025

EVOLVE 1

A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

PTCy-PMAT

Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies

Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan

HVA vs IA/DA or VA in the Treatment of ND HR-AML

Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

SCRIPT-AML

Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML

MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

Myechild01